A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS

M Hardmeier, L Leocani, P Fuhr

Research output: Contribution to journalArticle

Abstract

Evoked potentials (EP) characterize signal conduction in selected tracts of the central nervous system in a quantifiable way. Since alteration of signal conduction is the main mechanism of symptoms and signs in multiple sclerosis (MS), multimodal EP may serve as a representative measure of the functional impairment in MS. Moreover, EP have been shown to be predictive for disease course, and thus might help to select patient groups at high risk of progression for clinical trials. EP can detect deterioration, as well as improvement of impulse propagation, independently from the mechanism causing the change. Therefore, they are candidates for biomarkers with application in clinical phase-II trials. Applicability of EP in multicenter trials has been limited by different standards of registration and assessment. © 2017, © The Author(s), 2017.
Original languageEnglish
Pages (from-to)1309-1319
Number of pages11
JournalMultiple Sclerosis
Volume23
Issue number10
DOIs
Publication statusPublished - 2017

Fingerprint

Evoked Potentials
Multiple Sclerosis
Biomarkers
Clinical Trials
Phase II Clinical Trials
Multicenter Studies
Signs and Symptoms
Central Nervous System

Cite this

A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS. / Hardmeier, M; Leocani, L; Fuhr, P.

In: Multiple Sclerosis, Vol. 23, No. 10, 2017, p. 1309-1319.

Research output: Contribution to journalArticle

@article{c5f59514ba1d47dab1c750fd57cfd553,
title = "A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS",
abstract = "Evoked potentials (EP) characterize signal conduction in selected tracts of the central nervous system in a quantifiable way. Since alteration of signal conduction is the main mechanism of symptoms and signs in multiple sclerosis (MS), multimodal EP may serve as a representative measure of the functional impairment in MS. Moreover, EP have been shown to be predictive for disease course, and thus might help to select patient groups at high risk of progression for clinical trials. EP can detect deterioration, as well as improvement of impulse propagation, independently from the mechanism causing the change. Therefore, they are candidates for biomarkers with application in clinical phase-II trials. Applicability of EP in multicenter trials has been limited by different standards of registration and assessment. {\circledC} 2017, {\circledC} The Author(s), 2017.",
author = "M Hardmeier and L Leocani and P Fuhr",
year = "2017",
doi = "10.1177/1352458517707265",
language = "English",
volume = "23",
pages = "1309--1319",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "10",

}

TY - JOUR

T1 - A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS

AU - Hardmeier, M

AU - Leocani, L

AU - Fuhr, P

PY - 2017

Y1 - 2017

N2 - Evoked potentials (EP) characterize signal conduction in selected tracts of the central nervous system in a quantifiable way. Since alteration of signal conduction is the main mechanism of symptoms and signs in multiple sclerosis (MS), multimodal EP may serve as a representative measure of the functional impairment in MS. Moreover, EP have been shown to be predictive for disease course, and thus might help to select patient groups at high risk of progression for clinical trials. EP can detect deterioration, as well as improvement of impulse propagation, independently from the mechanism causing the change. Therefore, they are candidates for biomarkers with application in clinical phase-II trials. Applicability of EP in multicenter trials has been limited by different standards of registration and assessment. © 2017, © The Author(s), 2017.

AB - Evoked potentials (EP) characterize signal conduction in selected tracts of the central nervous system in a quantifiable way. Since alteration of signal conduction is the main mechanism of symptoms and signs in multiple sclerosis (MS), multimodal EP may serve as a representative measure of the functional impairment in MS. Moreover, EP have been shown to be predictive for disease course, and thus might help to select patient groups at high risk of progression for clinical trials. EP can detect deterioration, as well as improvement of impulse propagation, independently from the mechanism causing the change. Therefore, they are candidates for biomarkers with application in clinical phase-II trials. Applicability of EP in multicenter trials has been limited by different standards of registration and assessment. © 2017, © The Author(s), 2017.

U2 - 10.1177/1352458517707265

DO - 10.1177/1352458517707265

M3 - Article

VL - 23

SP - 1309

EP - 1319

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 10

ER -